Plasmodium berghei: Combining folic acid antagonists for potentiation against malaria infections in mice

Kenneth E. Kinnamon, Arba L. Ager, Robert W. Orchard

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

The drugs 2,4-diamino-6-(2-naphthyl-sulfonyl)-quinazoline (WR 158,122)and its tetrahydro analog (WR 180,872) were found to act synergistically in reducing the parasitemia of Plasmodium berghei infected mice. Evidence was found that both the drugs which are potent folic acid antagonists were acting at different sites in the folic acid metabolic pathway, neither of which was at the action site of p-aminobenzoic acid (PABA)inhibitors. Advantages of drug combinations in malaria chemotherapy are discussed.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalExperimental Parasitology
Volume40
Issue number1
DOIs
StatePublished - Aug 1976

Keywords

  • Antifols
  • Chemotherapy, malaria
  • Combined drug therapy
  • Dihydrofolate reductase inhibitors
  • Drug antagonism
  • Drug combinations
  • Drug synergism
  • Enzymes
  • Folic acid
  • Inhibitors, metabolic
  • Malaria
  • Metabolic inhibitors
  • Mice
  • Plasmodium berghei
  • p-Aminobenzoic acid

ASJC Scopus subject areas

  • Parasitology
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Plasmodium berghei: Combining folic acid antagonists for potentiation against malaria infections in mice'. Together they form a unique fingerprint.

  • Cite this